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Abstract Chronic lymphocytic leukaemia (CLL) is well
known to generate impaired immune responses in the host,
with the malignant clone residing in well-vascularized tissues
and circulating in peripheral blood but also in close proximity
to effector cells that are capable, if activated appropriately, of
eliciting a cytotoxic response. These, combined with the fact
that this is frequently a condition affecting older patients with
co-morbidities often unfit for many Btraditional^ cytotoxic
agents with their significant associated toxicities, make CLL
an ideal candidate for the development of immunotherapy.
The impressive results seen with the addition of a monoclonal
antibody, rituximab, to a chemotherapy backbone, for exam-
ple, is testament to how effective harnessing an immune-
mediated response in CLL can be. This review serves to out-
line the available arsenal of immunotherapies—past and pres-
ent—demonstrated to have potential in CLL with some per-
spectives on how the landscape in this disease may evolve in
the future.
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Introduction
Cancer immunotherapy, described by the National Cancer In-
stitute (NCI) as any Bbiological therapy that uses substances to
stimulate or suppress the immune system to help the body
fight cancer…^, has been the subject of intense scientific in-
terest over the past three decades [1]. Many acknowledge that
hematologic malignancies, with cells that are readily isolated
and manipulated, developing in close proximity to sites of or
arising from cells involved with immune response and recog-
nition, have paved the way for understanding and innovation
in this field [2••].
Treatment options for patients with chronic lymphocytic
leukaemia (CLL) have evolved over time, from alkylator-
based chlorambucil or cyclophosphamide in the 1970s to
combinations with purine analogues in the 1990s [3, 4]. Sim-
ilar to other cancers, a therapeutic ceiling was reached with
addition of further traditional Bchemotherapy^ not translating
into improvements in overall responses (OR) or survival (OS)
[3]. The introduction of immunotherapy (in the form of a
monoclonal antibody targeting CD20, rituximab) to a chemo-
therapeutic backbone demonstrated significant improvements
in OR and OS rates in the front line setting [5] and established
its role in the treatment paradigm.
For today’s patients, the future has never been brighter and
recent therapeutic improvements in CLL were labelled by the
American Society of Clinical Oncology (ASCO) as Bthe Can-
cer advance of the year^ in its annual report in 2015 [6]. In the
current era, it is highly unlikely that a newly diagnosed patient
with CLL will not be treated with some form of immunother-
apy during the course of their disease [7••], and the repertoire
of available immunotherapies to treat CLL is likely to increase
significantly over the coming years.
Although traditionally subdivided into Bpassive^ or
Bactive^ based on the ability to engage an immune response
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against malignant cells in the host, this may not be an entirely
accurate division [8]. Many passive immunotherapies will il-
licit cytokine release, generate tumour associated antigens
which will be taken up by antigen-presenting cells (APCs)
or require native immune cells to effect cell death [9•]. This
review will detail the scope of agents with the ability to gen-
erate an immune response and potential utility in CLL, includ-
ing those with an established role (e.g., anti-CD20monoclonal
antibodies/mAb) to novel strategies such as checkpoint inhib-
itors and cellular therapies.
Monoclonal Antibodies
Antibodies cloned to target a tumour-specific antigen (TSA)
are possibly the best characterized and most extensively
employed immunotherapy currently in CLL. Numerous tar-
gets exist to selectively target B cells—such as CD20, CD19
and CD37. Composed of a fixed effector cell binding region
(Fc) and a variable region with specificity for the TSA, these
large molecules act to recruit an immune response predomi-
nantly by opsonising cancer cells, flagging them for destruc-
tion by effector cells via antibody dependent cell-mediated
cytotoxicity (ADCC) and antibody-dependent cellular phago-
cytosis (ADP) [3]. Recruitment of the complement cascade or
complement-dependent cytotoxicity (CDC) to varying de-
grees also plays a role in the cell death initiated by these agents
[10, 11]—Fig. 1. Advances in technology have led to the
development of fully humanized and glycoengineered anti-
bodies with even greater specificity for the TSA and enhanced
recruitment of the immune response with associated improve-
ments in clinical efficacy [12–15].
Anti-CD20 Monoclonal Antibodies (Rituximab,
Ofatumumab, Obinutuzumab)
CD20 is a hydrophobic glycosylated transmembrane protein
present on the cell surface of mature B lymphocytes [16] but
not stem cells, pro-B cells or plasma cells [17]. It has no
natural ligand [18], and although both CD19-induced calcium
responses and B cell receptor signaling is altered in CD20
knockout mice [19], its exact function remains poorly eluci-
dated. However, it appears to be neither shed nor internalized
[20], and its specificity for B cells makes it the perfect target to
treat B cell neoplasms.
The first approved therapeutic antibody for the treatment of
malignancy [3], rituximab, is an IgG1 κ chimeric immuno-
globulin containing both murine light- and heavy-chain vari-
able region sequences with human constant region sequences.
It is thought to exert its cytotoxic effects on CD20-expressing
B cells chiefly by ADCC, ADP and to a lesser extent via CDC
[10, 11].
Although it had limited success as a single agent [21],
further investigation into its use in CLL proved its efficacy
across a variety of combination strategies in phase II and III
clinical trials and cemented its place in the treatment of both
treatment-naive and relapsed patients [5, 7••, 22, 23]. It re-
mains a crucial component of the Bgold standard^ for patients
with CLL who are deemed Bfit^ for full-dose fludarabine, as
part of the Fludarabine Cyclophosphamide Rituximab (FCR)
regime, and this strategy has yet to be outperformed in
terms of OR and OS rates in the frontline setting, al-
though it is not suitable for patients who have a 17p
deletion or TP53 mutation [7••].
Ofatumumab is a fully humanized mAb that targets a dif-
ferent epitope on the CD20 molecule than rituximab and has a
slower dissociation rate, greater CDC and similar ADCC
properties [24]. Although it was granted approval in the treat-
ment of fludarabine- and alemtuzumab-refractory patients by
the EMA and the FDA [7••, 25], its uptake as a single agent in
this patient population has now been limited given the inferior
Fig. 1 Mechanism of action of immunotherapies available in CLL. 1.
Monoclonal antibodies (Mabs) act via several mechanisms to recruit an
immune response, targeting a tumour-specific antigen (TSA) and gener-
ating to varying degrees depending on the antibody: complement activa-
tion (CDC), activation of cytotoxic effector cells via the Fc gamma re-
ceptor (ADCC) or activating phagocytosis (ADP). 2. Bi-specific T cell
engaging antibodies activate T cells in close proximity to the malignant
clone—one portion is specific for the TSA on the clone and will only bind
to the CD3 receptor on the T cells when the TSA fragment is bound, thus
limiting the T cell response to sites of disease. 3. Adaptive T cell transfer
with chimeric antigen receptor T cells allows for the re-infusion of autol-
ogous T cells primed to recognize a TSA that will generate a T cell
response upon binding due to the co-stimulatory domains that are built
into the receptor complex. 4. Blockade or downregulation of PD-1 by
either a monoclonal antibody or through the action of immunomodulatory
agents like lenolidomide overcomes the inhibition of Tcells and generates
an immune response against the malignant clone. Mab monoclonal anti-
body, CDC complement dependent cytotoxicity, ADCC antibody depen-
dent cellular cytotoxicity, ADP antibody dependent phagocytosis, MAC
membrane attack complex, BiTE bi-specific T cell engaging antibody,
CAR chimeric antigen receptor, IMiD immunomodulatory drug, PD-1
programmed cell death-1
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activity of this agent in comparison with ibrutinib, also in a
randomized clinical trial that led to regulatory approval of this
Bruton’s tyrosine kinase (BTK) inhibitor [26]. Ofatumumab
has also been granted FDA approval for the treatment of ther-
apy-naïve Bunfit^ patients, i.e., those deemed unsuitable for
full-dose fludarabine-based therapy in the upfront setting
when given in combination with oral chlorambucil. Compared
to chlorambucil monotherapy, the combination offered a sig-
nificant improvement in OR rates (82 vs 69 %) and
progression-free survival (PFS; 22.4 vs 13.1 months) [27].
Obinutuzumab is also fully humanized but is also
glycoengineered to reduce the fucose content of the Fc por-
tion, to enhance the binding of the Fcgamma receptor on ef-
fector cells and increase cytotoxic potency via ADCC and
ADP mechanisms [12–14, 28, 29]. When directly compared
to either chlorambucil monotherapy or a combination of
chlorambucil and rituximab (R-CLB), the combination of
obinutuzimab and chlorambucil (G-CLB) outperformed both
treatment arms in unfit previously untreated patients and the
head-to-head comparison between G-CLB and R-CLB
achieved a statistically significant improvement of PFS (29.2
vs 15.4 months, respectively) with a significantly higher num-
ber of complete responses in the G-CLB group (20.7 vs 7.0%)
[15, 30]. Whether these results will translate into a greater
tendency to use this regime over ofatumumab with
chlorambucil remains to be seen, but both regimens have ap-
proval in the frontline setting for this unfit patient population
[25]. Further clinical trials comparing obinutuzumab using
alternative combinations are ongoing, and whether it will con-
tinue to outperform rituximab in other settings remains to be
seen.
Anti-CD52 (Alemtuzumab)
Alemtuzumab is a fully humanized IgG1 monoclonal anti-
body directed against the heavily glycosylated transmembrane
glycoprotein, CD52. Unlike CD20, this antigen is not restrict-
ed to B cells and is expressed also by T lymphocytes,
granulocytes, monocytes and macrophages as well as NK
and dendritic cells [31]. Alemtuzumab exerts its cytotoxic
activity primarily through CDC [31, 32] and ADCC [33] but
has also been demonstrated to induce cell death via a direct
mechanism that was independent of TP53 status [34], a find-
ing which was later corroborated by clinical activity in this
difficult-to-treat group with 17p deletion or TP53 mutations
[35, 36]. It appears to have the greatest efficacy in those pa-
tients with greater circulating disease or bone marrow infiltra-
tion, with poorer responses in those patients with bulky lymph
nodes (LN) (>5 cm in particular). Whether this is the result of
poor penetration of this molecule into nodal tissue or the result
of impaired recruitment of an immune response due to lower
effector cell density in LNs is postulated but remains
unproven [3]. Although it had approval to treat patients with
CLL and continues to be described as a therapeutic option, a
strategic decision by Sanofi has led to its withdrawal from the
market for this indication and it can only be accessed via a
compassionate use program [7••].
Novel TSATargets: Mabs Directed Against CD19,
CD37, CD40
A transmembrane glycoprotein found on a wide range of B
cell malignancies, CD19, is highly expressed in CLL and thus
attractive TSA target for immunotherapies [37]. It acts as a co-
stimulatory molecule for the B cell receptor, and development
of mAbs was initially hampered by antigen internalization
[38]. Improved technology has led to the development of a
series of modified antibodies that re-instated its value as a
potential target. MEDI-551, an afucosylated anti-CD19 anti-
body that acts predominantly via ADCC and demonstrated a
30 % response rate in CLL as a monotherapy, is under inves-
tigation in combination with bendamustine in a phase II set-
ting in patients with relapsed/refractory (RR) CLL
(NCT01466153). Preliminary analysis has reported clinical
activity and comparable safety when compared to rituximab
and bendamustine [39]. XmAb5574 (MOR00208) is another
anti-CD19 mAb with an engineered Fc region to enhance
ADCC and ADP [38]. Phase I evaluation as a monotherapy
(NCT01161511) also demonstrated a 30 % response rate in
RRCLL patients and acceptable toxicity. Its combination with
lenolidomide is under investigation in a phase II setting
(NCT02005289).
CD37 is another lineage-specific B cell TSA that is a prime
candidate for targeted development. Otlertuzumab (TRU-016)
is a novel small modular immunopharmaceutical (SMIP) that
targets CD37 and demonstrates efficient ADCC and caspase-
independent cytotoxicity that spares T cells, in contrast to
alemtuzumab [40]. In a phase I dose escalation study
(NCT00614042) involving patients with RR CLL, a 23 %
response rate was seen and authors reported acceptable toxic-
ity [41]. Further studies investigating its use in RR CLL pa-
tients in combination with bendamustine or anti-CD20 mAbs
are ongoing [42].
CD40, a member of the tumour necrosis factor receptor
superfamily, is expressed by 90–100 % of CLL cells [43],
and its activation has been associated with enhanced survival
of neoplastic B cells; triggering phosphorylation of ERK 1/2
and upregulating Mcl-1 and Bcl-xl and it may have a role in
resistance to chemotherapy [44]. Lucatumumab (HCD122) is
a humanized anti-CD40 antagonist that blocks the receptor
from interacting with its natural ligand (CD40L) as well as
mediating ADCC. In a phase I evaluation of patients with RR
CLL, stable disease was observed in 17/26 patients with ac-
ceptable toxicity [45]. Despite the promise of initial pre-
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clinical work on another anti-CD40 mAb, dacetuzumab
(SGN40), demonstrating ADCC that was further enhanced
by combining it with lenolidomide [46], development beyond
a phase I dose escalation study appears to have been halted in
CLL after it demonstrated minimal clinical activity as a single
agent [47].
Bi-Specific T cell Engager (BiTE®): Blinatumomab
Blinatumomab is a recombinant fusion single-chain antibody
with bi-specific properties, composed of an anti-CD3 frag-
ment linked to an anti-CD19 fragment; this novel antibody
has the ability to opsonise CD19+ cells and promote direct
immune synapse formation with T cells [48]—Fig. 1. This
novel construct, known as a bi-specific T cell engager
(BiTE®), has already demonstrated impressive clinical effica-
cy in the treatment of relapsed or refractory acute lymphoblas-
tic leukaemia and has received FDA approval for this indica-
tion [49]. Studies in indolent non-Hodgkin’s lymphoma and
diffuse large B cell lymphoma are ongoing and provisional
results are encouraging [50, 51]. Given the known T cell dys-
function in patients with CLL, there might be a theoretical
obstacle against using this agent in this population [52•].
However, preliminary work demonstrated that the agent is
active at least in vitro, in CLL samples with an Bexhausted^
Tcell population [48]. Despite these findings, there appears to
be no active plans, at least at the present, to explore the activity
of this agent in vivo in a CLL population [42] whichmay have
more to do with the competitive landscape in CLL than the
probability of clinical efficacy.
Immune Checkpoint Inhibitors: Anti-PD1/PD-L1
Antibodies
The discovery that malignant cells can evade the host immune
system and its tumour surveillance mechanisms by inhibiting
T cells has led to the development of a totally new class of
immunotherapy—immune checkpoint inhibitors. Pro-
grammed cell death 1 (PD-1; CD279) and its ligands pro-
grammed death-ligand 1 (PD-L1; B7-H1; CD274) and PD-
L2 (B7-DC; CD273) have been identified as possibly the most
important axis in the maintenance of a malignant pro-survival
microenvironment [53]. CLL cells have been shown to upreg-
ulate PD-L1 expression and suppress host T cell effector re-
sponses, exacerbating the development of an Bexhausted^ T
cell phenotype, which overexpresses the PD-1 receptor and
rendered incapable of attacking the malignant clone [52•, 54•,
55•]. Given the recent success using antibodies that can inter-
fere with this immunosuppressive pathway in both Hodgkin’s
[56] and non-Hodgkin’s lymphomas [57] and the weighty pre-
clinical evidence referenced above, it seems clear that
interference with this pathway should benefit patients with
CLL. It seems unlikely that these antibodies would be devel-
oped as a monotherapy, but instead combined with other
agents, for example, BTK inhibitors. Pre-clinical data have
demonstrated synergy [58] with dual inhibition and a clinical
trial (NCT02420912) involving relapsed, refractory or high-
risk treatment-naive patients with CLL and the combination of
ibrutinib and nivolumab (humanized IgG4 anti-PD-1 mono-
clonal antibody) is currently recruiting.
Immunomodulatory Agent: Lenalidomide
The effects of lenalidomide, a second-generation thalidomide
analogue and classified as an immunomodulatory drug
(IMiD), have been increasingly well characterized over the
past two decades [59]. Although IMiDs have some intrinsic
anti-neoplastic activity, they are better considered as active
immunotherapies [9•]. Lenalidomide has the ability to reverse
the T cell dysfunction observed in patients with CLL in vitro,
as well as to induce downregulation of PD-1 on these defec-
tive T cells and reduce PDL-1 expression by the malignant
CLL clone [60•, 61]. These actions restore T cell effector
function in addition to providing rationale for the combination
of this agent with mAbs that interfere with the PD-1/PDL-1
axis.
Clinically, lenalidomide as a single agent has demonstrated
responses in 56 % of previously untreated CLL patients [62]
with encouraging activity in patients with high-risk cytogenet-
ics such as del 17p [63]. Combination with rituximab (the so-
called R-squared regimen) has been shown to further improve
upon these responses, with OR rates of 83 % including in
those with unmutated IGHV and del 17p [64]. Combinations
with more traditional agents used to treat CLL such as
fludarabine and bendamustine have not been as well tolerated,
with trials stopped prematurely as a result of the unacceptable
toxicities observed [7••, 65]. A unique toxicity in this patient
population is the occurrence of Btumour flare^—acute swell-
ing of involved lymph nodes accompanied by an inflammato-
ry response in the overlying skin, rash and fever. This reaction
appears to be the result of improved B cell antigen presenta-
tion and correlates with clinical response and anti-tumour ac-
tivity provoked by lenalidomide [66]. Further combinations of
lenalidomide with anti-CD20 and anti-CD19 mAbs are being
explored in patients with CLL as well as investigation into its
use as a maintenance therapy or in those with high-risk but
early-stage disease [42].
Allogeneic Transplantation
The original Badaptive cellular immunotherapy ,^ allogeneic
haematopoietic stem cell transplantation (HSCT),
32 Curr Hematol Malig Rep (2016) 11:29–36
demonstrated the potential that inducing a durable T cell re-
sponse against a CLL clone can have [67]. Evidence for a
graft-versus-leukaemia (GVL) effect was demonstrated by
the lower relapse risk observed after chronic graft-versus-
host-disease (GVHD), increased relapse seen with T cell de-
pleting strategies [68, 69•] and MRD analyses demonstrating
that augmentation of GVL is possible with strategies such as
donor lymphocyte infusion (DLI) [70] and HSCT is still
regarded as one of the few treatment strategies with the poten-
tial to cure CLL.
The indications for allogeneic transplant in patients with
CLL established in 2007 by the Society for European Bone
Marrow Transplantation (EBMT) suggest its use in high-risk
patients with poor prognostic features, Bwho can expect a
significant reduction of life expectancy under alternative
therapies^ [71]. This translated into an indiction for younger,
fitter patients with fludarabine refractory disease, or those with
high-risk cytogenetics. Outcomes reported with increasing use
of reduced intensity regimens suggest approximate disease-
free survival (DFS) ranging between 36 and 43 % and OS
rates of 50–63% at 3–5 years in eligible patients who undergo
the procedure [72••].
However, in the current treatment era, with novel agents
ibrutinib, idelalisib and BCL2 antagonists demonstrating ac-
tivity in patients with high-risk CLL [7••, 69•], including those
with del 17p and p53 mutations, these guidelines are being
questioned and were recently reviewed in the light of this
shifting landscape [69•]. Despite improvements in condition-
ing regimens and supportive care, HSCT remains a procedure
with significant associated risk, with non-relapse mortality
(NRM) rates in the region of 15–30 % during the first 2 years
post-transplant, chiefly the result of infections and GVHD
[69•]. Nonetheless, many still consider HSCTas the treatment
of choice for eligible patients with high-risk disease [69•].
Adoptive Cellular Therapy: CAR-T Cells
Hailed as the ultimate weapon in the field of immunotherapy,
genetically engineered autologous T cells—or chimeric anti-
gen receptor (CAR) T cells—have been touted as the modern
alternative to allogeneic transplant [73]. Bespoke to every
patient, native T cells are harvested and engineered ex vivo
such that they are redirected to recognize a TSA in conjunc-
tion with a co-stimulatory motif. These cells are then expand-
ed and re-infused to generate an adoptive T cell-mediated
cytotoxic response—Fig. 1. Attempts to improve in vivo per-
sistence and the cytotoxic capability of CAR T cells have led
to the inclusion of either CD137 (4-1BB) or CD28 signaling
domains, and these so-called second generation CAR-T cells
have improved anti-tumour efficacy.
In the setting of CLL, the conditioning regimen and co-
stimulatory motif may be particularly important to ensure
expansion and persistence of the CAR-T cells post-transfer.
Regulatory T cells (Tregs) are expanded in CLL patients; thus,
it is likely that a conditioning regimen capable of eliminating
these and other detrimental subpopulations may be crucial
[74, 75]. In addition, the use of the CD137 co-stimulatory
domain appears less likely to trigger pro-inflammatory cyto-
kine release (e.g., IL-2 and TNFα) that can also promote the
differentiation of Tregs, and this strategy appears to improve
the persistence of transferred CARs in vivo [76].
CD19-directed CAR-Tcells have demonstrated impressive
clinical results both in acute lymphoblastic leukaemia [77, 78]
and an increasing number of patients with CLL [79]. Overall
response rates in relapsed and refractory CLL patients ap-
proaching 45 % have been reported by the group from the
University of Pennsylvania with long-term remissions ob-
served even in patients with bulky disease [72••]. Persistence
of CAR-T cells beyond 3 years has also been reported [79,
80]; thus, this therapy may hold promise for long-term disease
control. Future approaches that may prove efficacious in using
CAR-Tcells to treat patients with CLL (apart from optimizing
the conditioning regimen and CAR itself) may involve com-
bining CAR-T cells with checkpoint inhibitors, selecting
memory Tcells to enhance persistence or including transgenes
that protect the CARS from an inhibitory microenvironment
[72••, 81].
When directly compared to HSCT, CAR-T cells have two
key advantages, namely an absent risk of GVHD and lack of
requirement for long-term immunosuppression [72••]. The
downside is the induction of B cell aplasia since normal
CD19-expressing B cells are also eliminated. These patients
therefore require long-term immunoglobulin replacement.
However, considering the median age of CLL diagnosis lies
somewhere between 67 and 72 years of age [7••], many pa-
tients with high-risk features are not considered eligible for
HSCT due to the significant treatment-related mortality. These
patients might, in the future, be candidates for CAR-T cell
therapy, although it remains in the early stages of development
and technically challenging to deliver outside of specialist
centres.
Conclusion
What is clear from the data outlined above and the rapid de-
velopment in immunotherapy observed to date is that
directing the immune system to target a malignant clone can
be a very efficacious strategy. Haemato-oncology has been at
the forefront of immunotherapeutic innovation for decades,
and CLL is a condition that lends itself extremely well to the
investigation of various immune interventions with readily
accessible tissue from both malignant and infiltrating immune
cells [2••].
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A key underpinning feature of the immune system remains
that distinct effector subpopulations act in a co-ordinated fash-
ion to exert or amplify the immune response. Thus, it seems
likely that a multi-faceted, combination approach is what ul-
timately will be required to generate maximal benefits from
these novel agents. This strategy has already been adopted by
trials looking at combinations of anti-CD20 mAbs with anti-
PD1 antibodies or lenolidomide, and the number and variety
of combinations being tested in the clinic seems likely to con-
tinue to expand.
Another potential opportunity for development is in
the targeting of early-stage disease, generating an anti-
tumour response prior to the development of an immu-
nosuppressive, pro-neoplastic microenvironment. This
has been studied in the setting of advanced-stage,
asymptomatic, non-bulky follicular lymphoma using sin-
gle agent rituximab, with significant differences ob-
served in progression-free survival favouring those in
the rituximab-treated versus the Bwatch-and-wait^ arm
(hazard ratio 0.23, 95 % CI 0.16–0.32, p < 0.0001)
[82]. A trial involving patients with early-stage, asymp-
tomatic CLL and high-risk cytogenetics (del 17p or 11q)
using single agent lenalidomide was also attempted but
was unfortunately terminated early due to poor recruit-
ment (NCT01649791). Given what is known about tu-
mour burden augmenting immunotherapeutic resistance
through a variety of mechanisms, it would seem likely
that exploiting early recognition by the immune system
would have Bsubstantial therapeutic impact^ [2••].
With the advancement of diagnostic technology, such as
next-generation sequencing, it would not be unreasonable to
foresee that a more tailored and individual approach may be
possible in the future. Molecular signatures from both CLL
and immune cells could be profiled and used to identify opti-
mal immunotherapeutic strategies. As in other haematological
malignancies, the future for patients with CLL has never been
better. As our understanding of the nature of the immune de-
fects and survival pathways in this disease expands, so too
does the available therapeutic arsenal.What remains challeng-
ing is determining exactly how this vast array of novel immu-
notherapeutics will fit in to the rapidly changing treatment
paradigm.
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